Lantheus Holdings, Inc. (LNTH) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic
Hold if already holding. Not a fresh buy at $104.50, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Jubilant HollisterStier; Concentration risk — Product: PYLARIFY.
Lantheus Holdings is a radiopharmaceutical-focused company with three product categories: Radiopharmaceutical Oncology (PYLARIFY, F-18 PSMA PET for prostate cancer), Precision Diagnostics (DEFINITY ultrasound agent, Neuraceq Alzheimer's PET), and Strategic Partnerships/CDMO.... Read more
Hold if already holding. Not a fresh buy at $104.50, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Jubilant HollisterStier; Concentration risk — Product: PYLARIFY. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 6.0/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 53d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-06-13Recent Developments — Lantheus Holdings, Inc.
Latest news
- NEWS Analysts Are Bullish on Top Healthcare Stocks: IQVIA Holdings (IQV), Lantheus (LNTH) - The Globe and Mail — The Globe and Mail neutral
- NEWS Mizuho raises Lantheus stock price target to $115 amid sale talks By Investing.com - Investing.com South Africa — Investing.com South Africa positive
- NEWS Mizuho raises Lantheus stock price target to $115 amid sale talks - Investing.com — Investing.com positive
- NEWS Mizuho raises Lantheus stock price target to $115 amid sale talks - Investing.com Nigeria — Investing.com Nigeria positive
- NEWS Mizuho raises Lantheus stock price target to $115 amid sale talks - Investing.com Canada — Investing.com Canada positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierJubilant HollisterStier10-K Item 1A: 'We rely on Jubilant HollisterStier as a substantial supplier of DEFINITY.'
- HIGHProductPYLARIFY10-K Item 1A: 'Continued substantial revenue contribution from PYLARIFY is dependent on (A) the ability of positron emission tomography ("PET") manufacturing facilities ("PMFs") to manufacture PYLARIFY to meet product demand'
Material Events(8-K, last 90d)
- 2026-05-01Item 5.02LOWLantheus shareholders approved the Amended and Restated 2026 Equity Incentive Plan on April 30, 2026, adding 2,000,000 shares, renaming the plan, and updating director compensation limits. No officer departure or appointment.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $104.50, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Jubilant HollisterStier; Concentration risk — Product: PYLARIFY. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Target $102.48 (-1.9%), stop $97.38 (−7.3%), A.R:R -1.0:1. Score 6.0/10, moderate confidence.
Take-profit target: $102.48 (-2.0% upside). Target $102.48 (-1.9%), stop $97.38 (−7.3%), A.R:R -1.0:1. Stop-loss: $97.38.
Concentration risk — Supplier: Jubilant HollisterStier; Concentration risk — Product: PYLARIFY; Analyst target reached - limited upside remaining.
Lantheus Holdings, Inc. trades at a P/E of 24.9 (forward 16.3). TrendMatrix value score: 5.8/10. Verdict: Hold.
19 analysts cover LNTH with a consensus score of 4.1/5. Average price target: $105.
What does Lantheus Holdings, Inc. do?Lantheus Holdings is a radiopharmaceutical-focused company with three product categories: Radiopharmaceutical Oncology...
Lantheus Holdings is a radiopharmaceutical-focused company with three product categories: Radiopharmaceutical Oncology (PYLARIFY, F-18 PSMA PET for prostate cancer), Precision Diagnostics (DEFINITY ultrasound agent, Neuraceq Alzheimer's PET), and Strategic Partnerships/CDMO. Products are sold primarily in the U.S. to hospitals, imaging centers, and government facilities through a network of third-party PMFs.